Source comparison
MK-677 Sustained GH Elevation: Oral vs Injectable Secretagogue Comparison
The table below compares MK-677 to commonly used injectable growth hormone secretagogues across key pharmacological and practical research parameters. MK-677 (Ibutamoren) Oral 4–6 hours Once daily Preserved pulsatile, increased amplitude Minimal over 24 months
This comparison does not assign a generated winner or score.
- The table below compares MK-677 to commonly used injectable growth hormone secretagogues across key pharmacological and practical research parameters.
- MK-677 (Ibutamoren)
- Oral
- 4–6 hours
- Once daily
- Preserved pulsatile, increased amplitude
- Minimal over 24 months
- 60–90% from baseline
- High. Single daily dose, stable IGF-1, no injection required
- GHRP-6
- Subcutaneous injection
- ~20 minutes
- 2–3× daily
- Immediate spike, rapid decline
- Moderate after 2–4 weeks
- 20–40% (transient)
- Moderate. Requires multiple daily dosing, tachyphylaxis common
- Ipamorelin
- ~2 hours
- Sharp pulse, shorter duration
- Low to moderate
- 25–50% (transient)
- Moderate. More stable than GHRP-6, still requires frequent dosing
- CJC-1295 (with DAC)
- 6–8 days
- 1–2× weekly
- Prolonged elevation, blunted pulses
- Low
- 50–80% (sustained but not pulsatile)
- Low. Flattens physiological pulse pattern, not ideal for studying natural GH dynamics
- Hexarelin
- ~70 minutes
- Potent immediate spike
- High. Significant after 14 days
- 30–60% (transient, attenuates quickly)
- Low. Rapid desensitization limits chronic research use
- Recombinant GH
- ~3 hours
- No physiological pulsatility, sustained supraphysiological levels
- N/A (exogenous hormone)
- 100–200%+ (dose-dependent)
- Moderate. Useful for direct GH studies but suppresses endogenous production
- MK-677 offers the most practical profile for chronic research models requiring sustained GH elevation without the logistical burden of multiple daily injections or the confounding variable of receptor tachyphylaxis. The oral bioavailability. Approximately 60–70% in fasted conditions. Eliminates injection site variables, and the once-daily dosing schedule reduces handling stress in animal models and improves compliance in human trials. Injectable peptides like GHRP-6 and ipamorelin produce higher peak GH concentrations acutely, but their effects attenuate within weeks of continuous use, whereas MK-677 maintains consistent response for months to years.
- The preserved pulsatile pattern is MK-677's defining advantage for physiological research. Compounds like CJC-1295 with DAC (drug affinity complex) create prolonged GH elevation that more closely resembles continuous infusion than natural secretion, which confounds studies examining GH's role in circadian rhythm, sleep architecture, or metabolic switching. MK-677 sustained GH elevation maintains the body's intrinsic regulatory framework, making it the preferred tool for research into how GH pulse amplitude. Rather than total GH exposure. Influences outcomes like lipolysis, muscle protein synthesis, and glucose metabolism.